Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.
INTRODUCTION Poly (ADP-ribose) polymerase inhibitors (PARPis) can enhance antitumor immunity and improve the efficacy of immune checkpoint inhibitors (ICIs) through PD-L1 upregulation and STING pathway activation. However, the benefit of this combination in PD-L1-negative patients remains unclear. METHODS We conducte...